Genes2Me (G2M), a leading innovator in the in-vitro diagnostics (IVD) space, has appointed John Bishop to its Advisory Board. With decades of leadership in the diagnostics sector, Bishop brings valuable strategic insights that will support G2M’s global growth ambitions. In his new role, he will advise the company on product development, commercialization strategies, and international market expansion.
John Bishop is best known for his tenure as Chairman and CEO of Cepheid, where he played a pivotal role in positioning the company as a global leader in molecular diagnostics. His leadership ultimately led to Cepheid’s acquisition by Danaher Corporation in 2016 for $4 billion. G2M sees his extensive experience and track record in scaling disruptive healthcare technologies as a crucial asset as it plans its next phase of expansion.
Neeraj Gupta, Founder and CEO of G2M, expressed enthusiasm about the appointment, emphasizing that Bishop’s strategic acumen and industry expertise will be instrumental in strengthening the company’s global presence. This collaboration is expected to accelerate G2M’s roadmap and further its mission of delivering cutting-edge diagnostic solutions worldwide.